Format:
Online-Ressource (XVIII, 845 p.,187 figs. in 338 sep. illustr., 240 in color, digital)
ISBN:
9783540331773
Series Statement:
SpringerLink
Content:
Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
Content:
Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. In the past 30 years some of the most important signaling pathways linking specific angiogenic activities of tumor cells to fatal reactions of the patient's vascular system have been elucidated. Crucial targets for therapeutic intervention have been identified and validated. Based on these achievements targeted drug development programs have been implemented to interfere with tumor angiogenesis as an attractive strategy in cancer treatment. The first targeted anti-angiogenic drugs have been approved for a variety of solid metastasizing cancers. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
Note:
Includes bibliographical references and index
,
Front Matter; Tumor Angiogenesis: from Bench to Bedside; Vasculogenesis and Angiogenesis in Development; Guidance of Vascular and Neuronal Network Formation; The Angiogenic Switch in Tumorigenesis; Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor; Regulation of Angiogenesis and Vascular Homeostasis Through the Angiopoietin / Tie System; Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis; The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression
,
Platelet-derived Growth Factor: Impact on Physiological and Tumor AngiogenesisHypoxia and Tumour Angiogenesis; Hypoxia and Angiogenesis in Glioblastomas; Endogenous Inhibitors of Angiogenesis; Thrombospondins and Angiogenesis; Molecular and Cellular Aspects of Heparanase; Vessel Maturation and Perivascular Cells; Adhesion Molecules in the Vascular Cell Cross-Talk; Homing and Differentiation of Endothelial Progenitor Cells; Molecular Players in Lymphangiogenesis; The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis
,
Inflammation and Angiogenesis: Innate Immune Cells as Modulators of Tumor VascularizationArteriovenous Malformation in Mice and Men; Vascular Endothelial Growth Factor Antibodies for Anti-Angiogenic Therapy; Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy; Angiopoietin-2 Antagonists for Anti-Angiogenic Therapy; Anti-Angiogenic Therapy with Thrombospondins; The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer; Vascular Tumor Targeting
,
Molecular Imaging of Targets and Therapeutics in Tumour AngiogenesisImaging of Tumor Angiogenesis and Antiangiogenesis; Visualization of Microcirculation and Anti-Angiogenic Tumor Therapy; Cellular Actions of Angiogenesis Inhibitors on Blood Vessels; Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment; Metronomic Antiangiogenic Chemotherapy: Questions and Answers; The Development of Avastin; Clinical Development of Sorafenib (BAY 43-9006) VEGFR and RAF Inhibitor; Clinical Development of the VEGFR Signalling Inhibitor AZD2171
,
Clinical Development of Sunitinib MalateThe EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy; Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies; Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development; Integrins: Targets for Anti-Angiogenic Therapy; Thalidomide in Multiple Myeloma; Surrogate Markers of Angiogenesis; Vascular Disrupting Agents in Cancer Therapy; Back Matter
,
Animal Models and Preclinical Anti-Angiogenic Studies. Vascular Endothelial Growth Factor Antibodies for Anti-angiogenic Therapy / Hans-Peter Gerber, Megan E. Baldwin, and Farbod Shojaei ; Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer / Stephen R. Wedge and Juliane M. Jürgensmeier ; Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy / Peter Bohlen, Zhenping Zhu, and Daniel J. Hicklin ; Angiopoietin-2 Antagonists for Anti-Angiogenic Therapy / Paul E. Hughes, Anthony Polverino, Jonathan D. Oliner, and Richard L. Kendall ; Anti-Angiogenic Therapy with Thrombospondins / Jack Lawler ; The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer / Robert R. Langley, Sun-Jin Kim, and Isaiah J. Fidler ; Vascular Tumor Targeting / Dragan Grabulovski and Dario Neri ; Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis / James P.B. O'Connor, Daniela D. Rosa, Alan Jackson, and Gordon C. Jayson ; Imaging of Tumor Angiogenesis and Antiangiogenesis / Fabian Kiessling and Martin Krix ; Visualization of Microcirculation and Anti-Angiogenic Tumor Therapy / Marcus Czabanka and Peter Vajkoczy ; Cellular Actions of Angiogenesis Inhibitors on Blood Vessels / Peter Baluk, Beverly L. Falcón, Hiroya Hashizume, Barbara Sennino, and Donald M. McDonald ; Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment / Rakesh K. Jain and Dan G. Duda ; Metronomic Antiangiogenic Chemotherapy: Questions and Answers / Robert S. Kerbel, Urban Emmenegger, Shan Man, Raquel Munoz, Francesco Bertolini, and Yuval ShakedAnti-Angiogenic Tumor Therapy in Clinical Studies. The Development of Avastin / Robert Mass ; Clinical Development of Sorafenib (BAY 43-9006), a VEGFR and RAF Inhibitor / Dimitris Voliotis and J. Dumas ; Clinical Development of the VEGFR Signalling Inhibitor AZD2171 / Joachim Drevs and Clemens Unger ; Clinical Development of Sunitinib Malate / Isan Chen, Carlo Bello, and Zuleima Aguilar ; The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy / Klaas Hoekman, Hester van Cruijsen, and Guiseppe Giaccone ; Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies / Bruno Morgan and Mark A. Horsfield ; Vandetanib (ZACTIMA; ZD6474): Preclinical and Clinical Development / Alan Barge and Anderson J. Ryan ; Integrins: Targets for Anti-Angiogenic Therapy / Oliver Kisker ; Thalidomide in Multiple Myeloma / Thomas M. Moehler, Jens Hillengass, Axel Glasmacher, Hartmut Goldschmidt ; Surrogate Markers of Angiogenesis / Valentina Raia, Patrizia Mancuso, and Francesco Bertolini ; Vascular Disrupting Agents in Cancer Therapy / Gillian M. Tozer, Chryso Kanthou, and David J. Chaplin.
Additional Edition:
ISBN 9783540331766
Additional Edition:
Buchausg. u.d.T. Tumor angiogenesis Berlin : Springer, 2008 ISBN 9783540331766
Additional Edition:
ISBN 354033176X
Language:
English
Subjects:
Medicine
Keywords:
Tumorwachstum
;
Angiogenese
;
Tumor
;
Angiogenese
;
Aufsatzsammlung
DOI:
10.1007/978-3-540-33177-3
URL:
Volltext
(lizenzpflichtig)
Bookmarklink
